Kozma S C, Redmond S M, Fu X C, Saurer S M, Groner B, Hynes N E
Ludwig Institute for Cancer Research, Bern Branch, Inselspital, Switzerland.
EMBO J. 1988 Jan;7(1):147-54. doi: 10.1002/j.1460-2075.1988.tb02794.x.
A new chimeric oncogene, trk-2h, has been generated by recombination of two segments of MDA-MB231 human breast carcinoma cell line DNA after transfection in NIH/3T3 cells. The rearranged DNA segments form a fused transcriptional unit. Sequences at the 3' end are homologous to the tyrosine kinase receptor moiety found in the trk oncogene which resembles a truncated growth factor receptor lacking part of its extracellular domain (Martin-Zanca et al., 1986). The 5' sequence of the trk-2h oncogene is contributed by a gene which is expressed in all human cells tested, and is not related to any known gene. Transfection of the receptor kinase domain DNA fragment into NIH/3T3 cells generated another oncogene, trk-3mh, which contains a mouse-specific sequence fused 5' to the receptor kinase. All three trk recombinants have the receptor kinase moiety fused to an activating amino terminus at the same nucleotide in their transcriptional product.
通过将MDA-MB231人乳腺癌细胞系DNA的两个片段在NIH/3T3细胞中转染后进行重组,产生了一种新的嵌合致癌基因trk-2h。重排的DNA片段形成一个融合的转录单元。3'端的序列与trk致癌基因中发现的酪氨酸激酶受体部分同源,该部分类似于一个缺少部分细胞外结构域的截短生长因子受体(Martin-Zanca等人,1986年)。trk-2h致癌基因的5'序列由一个在所有测试的人类细胞中都表达的基因提供,且与任何已知基因无关。将受体激酶结构域DNA片段转染到NIH/3T3细胞中产生了另一种致癌基因trk-3mh,它包含一个在受体激酶5'端融合的小鼠特异性序列。所有三种trk重组体在其转录产物的同一核苷酸处,受体激酶部分都与一个激活的氨基末端融合。